Background & Aims
Methods
Results
Conclusions
Keywords
Abbreviations used in this paper:
dHAZ (change in height-for-age z score), EED (environmental enteric dysfunction), FARMS (factor analyses for robust microarray summarization), G-CSF (granulocyte colony–stimulating factor), HAZ (height-for-age z score), IRON (iterative rank order normalization), KEGG (Kyoto Encyclopedia of Genes and Genomes), mRNA (messenger RNA), %L (lactulose permeability), qPCR (quantitative polymerase chain reaction), RMA (robust multi-array average)UNICEF. Improving child nutrition. 1, 8–14 (2013). Available from: http://www.unicef.it/Allegati/Improving_Child_Nutrition.pdf.
Methods
Study Design
Eligible Subjects
Dual Sugar Absorption Testing
Stool Collection

Samples Chosen for Transcriptome Analyses
Enriching Fecal Samples for Exfoliated Enterocytes by Differential Centrifugation
Extracting and Assessing Enriched Fecal RNA
Assaying the Human Fecal Transcriptome on a High-Density Microarray
Affymetrix. DataSheet GeneChip® Human Transcriptome Array 2.0. Available from: http://media.affymetrix.com/support/technical/datasheets/hta_array_2_0_datasheet.pdf.
Processing Microarray Signals Into Robust Multi-Array Average, Iterative Rank Order Normalization, and Factor Analyses For Robust Microarray Summarization Data Sets
Identifying Transcripts Associated With EED by Correlation and Differential Expression
Identifying KEGG and Canonical Pathways Associated With EED
Interpreting Biologically Significant Transcripts and Pathways
Validation of Fecal Transcriptome Results
Affymetrix. Human transcriptome array 2.0-support materials. Sample data WT PLUS HTA 2.0 data on tissue panel samples (zip, 756 MB). Available from: http://www.affymetrix.com/support/technical/byproduct.affx?product=human_transcriptome.
Results
Subjects
Characteristic | Mean ± SD or N (%) |
---|---|
Male sex | 134 (52) |
Age, mo | 30.1 ± 11.2 |
Weight-for-height, z score | -0.1 ± 0.9 |
Height-for-age, z score | -2.3 ± 1.2 |
Caretaker is mother | 249 (96) |
Father is alive | 256 (99) |
Siblings | 3.2 ± 1.9 |
Individuals who sleep in the same room as the child | 3.1 ± 1.3 |
Home with a metal roof | 67 (26) |
Family owns a bicycle | 147 (57) |
Animals sleep in the house | 118 (46) |
Water from a clean source | 206 (80) |
Child uses pit latrine | 125 (48) |
Child has HIV infection | 3 (1) |
Mother reports child has loose stools | 4 (2) |
Lactulose:mannitol ratio | 0.3 ± 0.2 |
Urinary lactulose, % dose administered | 0.4 ± 0.3 |
Urinary mannitol, % dose administered | 6.7 ± 3.0 |
EED severity | |
Healthy | 60 (23) |
Intermediate EED | 157 (61) |
Severe EED | 42 (16) |

Human Fecal Messenger RNA Is Reproducibly and Reliably Measured by Microarray


Microarray Identified Biologically Relevant Transcripts and Pathways Associated With EED
Normalization method | %L correlated transcripts | Differentially expressed transcripts | Enriched KEGG pathways | Enriched canonical pathways |
---|---|---|---|---|
Criteria for inclusion | ANCOVA P < .01 | ANOVA P < .05 and fold-change > 1.1 | GAGE P < .01 and FDR < 0.25 | MetaCore P < .01 and FDR < 0.25 |
RMA | 637 (3.42%) | 141 (0.76%) | 17 (8.95%) | 8 (4.97%) |
IRON | 667 (3.58%) | 388 (2.08%) | 19 (10.00%) | 46 (28.57%) |
FARMS | 81 (0.43%) | 12 (0.06%) | 0 (0%) | 17 (10.56%) |
Gene symbol | Detected in 259 | Differential expression, healthy vs severe EED | Pearson correlation to %L | Spearman correlation to dHAZ | |||
---|---|---|---|---|---|---|---|
FC/P value (RMA) | FC/P value (IRON) | r/P value (RMA) | r/P value (IRON) | rho/P value (RMA) | rho/P value (IRON) | ||
ACSL1 | 26% | 1.16/.006 | 1.27/.003 | 0.18/.004 | 0.19/.002 | -0.05/.463 | -0.05/.480 |
AMICA1 | 23% | 1.12/.002 | 1.22/.000 | 0.20/.001 | 0.23/.000 | -0.10/.148 | -0.09/.218 |
AQP9 | 22% | 1.33/.003 | 1.39/.004 | 0.17/.006 | 0.17/.007 | -0.14/.038 | -0.12/.083 |
ARRB2 | 42% | 1.12/.009 | 1.14/.008 | 0.18/.003 | 0.18/.004 | -0.04/.590 | -0.07/.337 |
BCL2A1 | 26% | 1.44/.003 | 1.45/.008 | 0.18/.004 | 0.18/.003 | -0.09/.216 | -0.12/.087 |
BCL6 | 21% | 1.13/.005 | 1.16/.010 | 0.17/.007 | 0.18/.004 | -0.07/.280 | -0.10/.148 |
BIN2 | 30% | 1.15/.002 | 1.23/.002 | 0.18/.004 | 0.20/.001 | -0.10/.155 | -0.06/.423 |
CD53 | 20% | 1.20/.002 | 1.34/.001 | 0.17/.006 | 0.20/.001 | -0.13/.063 | -0.09/.186 |
CLEC7A | 19% | 1.11/.001 | 1.22/.001 | 0.20/.001 | 0.21/.001 | -0.16/.018 | -0.15/.033 |
CR1 | 16% | 1.13/.001 | 1.23/.000 | 0.21/.001 | 0.24/.000 | -0.06/.381 | -0.02/.770 |
CSF2RB | 18% | 1.10/.010 | 1.14/.006 | 0.16/.010 | 0.18/.004 | -0.07/.311 | -0.09/.180 |
CSF3R | 23% | 1.12/.001 | 1.19/.000 | 0.22/.000 | 0.25/.000 | -0.09/.176 | -0.13/.059 |
CST7 | 36% | 1.14/.001 | 1.18/.003 | 0.19/.002 | 0.18/.004 | -0.10/.148 | -0.12/.089 |
CXCR2 | 21% | 1.16/.002 | 1.24/.001 | 0.17/.005 | 0.19/.002 | -0.04/.529 | -0.10/.165 |
FAM157A | 24% | 1.17/.018 | 1.22/.022 | 0.17/.005 | 0.16/.008 | -0.04/.533 | -0.03/.639 |
FAM157B | 26% | 1.13/.003 | 1.25/.001 | 0.19/.002 | 0.21/.001 | 0.03/.683 | 0.04/.579 |
FCER1G | 24% | 1.17/.002 | 1.29/.001 | 0.19/.002 | 0.21/.001 | -0.08/.229 | -0.12/.082 |
FCGR1B | 19% | 1.16/.003 | 1.25/.003 | 0.19/.002 | 0.18/.004 | -0.07/.320 | -0.05/.458 |
FCGR2A | 25% | 1.19/.002 | 1.31/.001 | 0.19/.002 | 0.19/.002 | -0.15/.035 | -0.14/.049 |
FCGR3B | 23% | 1.29/.002 | 1.39/.001 | 0.19/.002 | 0.18/.003 | -0.18/.008 | -0.20/.003 |
FFAR2 | 15% | 1.33/.001 | 1.38/.002 | 0.19/.002 | 0.18/.005 | -0.07/.311 | -0.01/.887 |
FPR1 | 11% | 1.24/.000 | 1.31/.000 | 0.19/.002 | 0.20/.002 | -0.11/.116 | -0.08/.240 |
GPR84 | 20% | 1.11/.006 | 1.15/.015 | 0.16/.010 | 0.16/.009 | -0.11/.097 | -0.10/.143 |
IFI30 | 24% | 1.24/.002 | 1.30/.002 | 0.20/.001 | 0.20/.001 | -0.06/.378 | -0.05/.461 |
IFITM1 | 41% | 1.21/.001 | 1.32/.002 | 0.19/.002 | 0.20/.001 | -0.19/.006 | -0.18/.008 |
IFITM2 | 48% | 1.42/.001 | 1.51/.001 | 0.20/.001 | 0.20/.001 | -0.14/.041 | -0.15/.024 |
IFITM3 | 45% | 1.31/.001 | 1.38/.001 | 0.19/.003 | 0.20/.001 | -0.11/.097 | -0.16/.023 |
IL1RN | 18% | 1.14/.001 | 1.24/.002 | 0.17/.007 | 0.17/.005 | -0.13/.057 | -0.11/.106 |
LAPTM5 | 13% | 1.24/.002 | 1.28/.004 | 0.18/.003 | 0.17/.005 | -0.06/.423 | -0.07/.328 |
LCP1 | 16% | 1.17/.003 | 1.25/.003 | 0.19/.002 | 0.19/.002 | -0.10/.153 | -0.09/.201 |
LYN | 26% | 1.17/.008 | 1.27/.005 | 0.19/.003 | 0.19/.002 | -0.14/.046 | -0.15/.031 |
LYZ | 22% | 1.27/.000 | 1.41/.001 | 0.18/.004 | 0.17/.007 | -0.10/.134 | -0.16/.023 |
MNDA | 30% | 1.33/.004 | 1.52/.004 | 0.17/.007 | 0.17/.007 | -0.18/.009 | -0.18/.009 |
MSN | 29% | 1.11/.004 | 1.18/.002 | 0.17/.006 | 0.20/.001 | -0.11/.114 | -0.15/.030 |
NCF2 | 15% | 1.20/.000 | 1.29/.000 | 0.24/.000 | 0.22/.000 | -0.12/.080 | -0.15/.034 |
NOP10 | 46% | 1.12/.007 | 1.21/.001 | 0.17/.007 | 0.21/.001 | 0.00/.981 | -0.13/.062 |
OR52D1 | 18% | 1.13/.001 | 1.15/.022 | 0.24/.000 | 0.18/.005 | -0.08/.278 | -0.06/.401 |
PIK3AP1 | 24% | 1.13/.004 | 1.22/.001 | 0.19/.002 | 0.21/.001 | -0.01/.850 | -0.06/.351 |
PLEK | 39% | 1.67/.003 | 1.56/.010 | 0.18/.003 | 0.17/.007 | -0.14/.042 | -0.11/.117 |
PROK2 | 26% | 1.27/.000 | 1.34/.001 | 0.19/.003 | 0.18/.004 | -0.08/.249 | -0.14/.040 |
S100A12 | 10% | 1.22/.006 | 1.31/.008 | 0.18/.004 | 0.17/.005 | -0.10/.143 | -0.08/.276 |
S100A8 | 27% | 1.17/.004 | 1.39/.002 | 0.17/.008 | 0.18/.004 | -0.13/.051 | -0.14/.045 |
SAMSN1 | 24% | 1.14/.022 | 1.30/.001 | 0.17/.005 | 0.21/.001 | -0.12/.095 | -0.18/.008 |
SDCBP | 25% | 1.20/.006 | 1.36/.009 | 0.19/.003 | 0.17/.006 | -0.10/.148 | -0.11/.118 |
SELL | 19% | 1.24/.001 | 1.43/.000 | 0.19/.002 | 0.24/.000 | -0.15/.032 | -0.16/.017 |
SLC2A3 | 26% | 1.16/.006 | 1.25/.005 | 0.18/.004 | 0.18/.004 | -0.12/.085 | -0.13/.070 |
SOCS3 | 13% | 1.12/.003 | 1.13/.005 | 0.18/.003 | 0.18/.004 | -0.03/.627 | -0.08/.277 |
SORL1 | 24% | 1.17/.002 | 1.23/.005 | 0.20/.001 | 0.19/.002 | -0.11/.101 | -0.12/.094 |
TAGAP | 23% | 1.15/.007 | 1.24/.007 | 0.17/.008 | 0.19/.002 | -0.10/.144 | -0.07/.319 |
VNN2 | 18% | 1.15/.002 | 1.25/.002 | 0.20/.001 | 0.21/.001 | -0.11/.101 | -0.12/.092 |
XPO6 | 21% | 1.16/.002 | 1.21/.007 | 0.20/.002 | 0.19/.002 | -0.04/.591 | -0.06/.372 |
Target | N (ddPCR) | Correlation between droplet digital PCR and microarray (IRON) | Correlation between droplet digital PCR and microarray (RMA) | ||
---|---|---|---|---|---|
Spearman correlation coefficient/significance (2-tailed) | Pearson correlation coefficient/significance (2-tailed) | Spearman correlation coefficient/significance (2-tailed) | Pearson correlation coefficient/significance (2-tailed) | ||
ACSL1 | 39 | 0.833/0.000 | 0.559/0.000 | 0.818/0.000 | 0.607/0.000 |
AQP9 | 39 | 0.699/0.000 | 0.636/0.000 | 0.725/0.000 | 0.669/0.000 |
BCL2A1 | 39 | 0.726/0.000 | 0.726/0.000 | 0.743/0.000 | 0.763/0.000 |
CD53 | 39 | 0.706/0.000 | 0.619/0.000 | 0.753/0.000 | 0.648/0.000 |
CSF3R | 24 | 0.785/0.000 | 0.654/0.001 | 0.746/0.000 | 0.798/0.000 |
IFI30 | 39 | 0.698/0.000 | 0.467/0.003 | 0.701/0.000 | 0.478/0.002 |
IL1RN | 36 | 0.801/0.000 | 0.743/0.000 | 0.739/0.000 | 0.632/0.000 |
LAPTM5 | 39 | 0.718/0.000 | 0.565/0.000 | 0.690/0.000 | 0.644/0.000 |
LCP1 | 33 | 0.835/0.000 | 0.583/0.000 | 0.837/0.000 | 0.584/0.000 |
LYN | 39 | 0.833/0.000 | 0.531/0.001 | 0.843/0.000 | 0.532/0.000 |
LYZ | 39 | 0.684/0.000 | 0.501/0.001 | 0.672/0.000 | 0.535/0.000 |
MNDA | 25 | 0.775/0.000 | 0.513/0.009 | 0.778/0.000 | 0.496/0.012 |
PIK3AP1 | 39 | 0.802/0.000 | 0.741/0.000 | 0.843/0.000 | 0.714/0.000 |
PLEK | 39 | 0.883/0.000 | 0.615/0.000 | 0.885/0.000 | 0.666/0.000 |
SELL | 41 | 0.808/0.000 | 0.580/0.000 | 0.802/0.000 | 0.611/0.000 |
SLC2A3 | 33 | 0.761/0.000 | 0.557/0.001 | 0.710/0.000 | 0.626/0.000 |
SORL1 | 33 | 0.648/0.000 | 0.569/0.001 | 0.694/0.000 | 0.656/0.000 |
TAGAP | 39 | 0.811/0.000 | 0.517/0.001 | 0.841/0.000 | 0.57/0.000 |
Gene symbol | Description | Cell adhesion | Viral response | Bacterial response | Parasite response | Fungal response | Localized to small intestine |
---|---|---|---|---|---|---|---|
ACSL1 | Acyl-CoA synthetase long-chain family member 1 | ||||||
AMICA1 | Adhesion molecule, interacts with CXADR antigen 1 | X | X | X | |||
AQP9 | Aquaporin 9 | X | |||||
ARRB2 | Arrestin, β 2 | X | |||||
BCL2A1 | BCL2-related protein A1 | X | X | ||||
BCL6 | B-cell CLL/lymphoma 6 | X | |||||
BIN2 | Bridging integrator 2 | X | |||||
CD53 | CD53 molecule | X | X | X | X | ||
CLEC7A | C-type lectin domain family 7, member A | X | |||||
CR1 | Complement component (3b/4b) receptor 1 (Knops blood group) | X | X | X | |||
CSF2RB | Colony-stimulating factor 2 receptor, β, low-affinity | X | X | ||||
CSF3R | Colony-stimulating factor 3 receptor (granulocyte) | X | X | X | |||
CST7 | Cystatin F (leukocystatin) | X | X | ||||
CXCR2 | Chemokine (C-X-C motif) receptor 2 | X | X | X | |||
FAM157A | Family with sequence similarity 157, member A | ||||||
FAM157B | Family with sequence similarity 157, member B | ||||||
FCER1G | Fc fragment of IgE, high-affinity I, receptor for; γ polypeptide | X | |||||
FCGR1B | Fc fragment of IgG, high-affinity Ib, receptor (CD64) | X | X | ||||
FCGR2A | Fc fragment of IgG, low-affinity IIa, receptor (CD32) | X | X | ||||
FCGR3B | Fc fragment of IgG, low-affinity IIIb, receptor (CD16b) | X | X | ||||
FFAR2 | Free fatty acid receptor 2 | X | X | X | |||
FPR1 | Formyl peptide receptor 1 | X | |||||
GPR84 | G-protein–coupled receptor 84 | X | X | X | |||
IFI30 | Interferon, γ-inducible protein 30 | X | |||||
IFITM1 | Interferon-induced transmembrane protein 1 | X | |||||
IFITM2 | Interferon-induced transmembrane protein 2 | X | |||||
IFITM3 | Interferon-induced transmembrane protein 3 | X | |||||
IL1RN | Interleukin 1–receptor antagonist | X | X | ||||
LAPTM5 | Lysosomal protein transmembrane 5 | X | |||||
LCP1 | Lymphocyte cytosolic protein 1 (L-plastin) | X | X | X | |||
LYN | V-yes-1 Yamaguchi sarcoma viral-related oncogene homolog | X | X | X | |||
LYZ | Lysozyme | X | |||||
MNDA | Myeloid cell nuclear differentiation antigen | X | |||||
MSN | Moesin | X | X | ||||
NCF2 | Neutrophil cytosolic factor 2 | X | |||||
NOP10 | NOP10 ribonucleoprotein | ||||||
OR52D1 | Olfactory receptor, family 52, subfamily D, member 1 | ||||||
PIK3AP1 | Phosphoinositide-3-kinase adaptor protein 1 | X | X | ||||
PLEK | Pleckstrin | ||||||
PROK2 | Prokineticin 2 | X | |||||
S100A12 | S100 calcium binding protein A12 | X | X | X | X | ||
S100A8 | S100 calcium binding protein A8 | X | X | X | X | ||
SAMSN1 | SAM domain, SH3 domain and nuclear localization signals 1 | X | X | ||||
SDCBP | Syndecan binding protein (syntenin) | X | |||||
SELL | Selectin L | X | X | ||||
SLC2A3 | Solute carrier family 2 (facilitated glucose transporter), member 3 | ||||||
SOCS3 | Suppressor of cytokine signaling 3 | X | X | X | X | ||
SORL1 | Sortilin-related receptor, L (DLR class) A repeats containing | ||||||
TAGAP | T-cell activation RhoGTPase activating protein | X | |||||
VNN2 | Vanin 2 | X | |||||
XPO6 | Exportin 6 |

Gene symbol | Gene description | Pathway category | r/P value (IRON) | r/P value (RMA) |
---|---|---|---|---|
BCL2A1 | BCL2-related protein A1: retards apoptosis induced by interleukin 3 deprivation | Physiologic stress | 0.184/.003 | 0.181/.003 |
FCGR3B | Fc fragment of IgG, low-affinity IIIb, receptor (CD16b): binds to Fc region of immunoglobulins gamma. Low-affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Not capable of mediating antibody-dependent cytotoxicity and phagocytosis | Phagocytosis | 0.184/.003 | 0.189/.002 |
IFITM1 | Interferon-induced transmembrane protein 1: antiviral protein that inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses | Response to viral invasion | 0.198/.001 | 0.188/.002 |
FCGR2A | Fc fragment of IgG, low-affinity IIa, receptor (CD32): binds to the Fc region of IgG. Binds to IgG and initiates cellular responses against pathogens and soluble antigens | Phagocytosis | 0.190/.002 | 0.189/.002 |
NCF2 | Neutrophil cytosolic factor 2: required for activation of the latent NADPH oxidase | Phagocytosis | 0.217/.001 | 0.237/.001 |
FCER1G | Fc fragment of IgE, high-affinity I, receptor for; γ polypeptide: the high-affinity IgE receptor is a key molecule involved in allergic reactions | Response to viral invasion | 0.214/.001 | 0.190/.002 |
LYN | V-yes-1 Yamaguchi sarcoma viral-related oncogene homolog: nonreceptor tyrosine-protein kinase. Plays an important role in the regulation of B-cell differentiation, proliferation, survival, and apoptosis, and is important for immune self-tolerance | Response to infection | 0.192/.002 | 0.187/.003 |
CXCR2 | Chemokine (C-X-C motif) receptor 2: integral membrane proteins that specifically bind and respond to cytokines of the CXC chemokine family. Receptor for interleukin 8, which is a powerful neutrophil chemotactic factor. Binds to interleukin 8 with high affinity | Physiologic stress | 0.190/.002 | 0.173/.005 |
PIK3AP1 | Phosphoinositide-3-kinase adaptor protein 1: signaling adapter that contributes to B-cell development, controls excessive inflammatory cytokine production by linking TLR signaling to PI3K activation | Response to viral invasion | 0.211/.001 | 0.188/.002 |
CLEC7A | C-type lectin domain family 7, member A: functions as a pattern-recognition receptor for a variety of β-1,3-linked and β-1,6-linked glucans, such as cell wall constituents from pathogenic bacteria and fungi, and plays a role in innate immune response. Stimulates T-cell proliferation | Phagocytosis | 0.212/.001 | 0.201/.001 |
ARRB2 | Arrestin, β 2: functions in regulating agonist-mediated desensitization of G-protein–coupled receptor and cause specific dampening of cellular responses to stimuli such as hormones, neurotransmitters, or sensory signals | Physiologic stress | 0.180/.004 | 0.182/.003 |
SOCS3 | Suppressor of cytokine signaling 3: negative regulator of JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, interleukin 12, G-CSF, and leptin receptors | Physiologic stress | 0.181/.003 | 0.182/.003 |

Discussion

Acknowledgments
Supplementary Material
- Supplementary Table 1–3

References
UNICEF. Improving child nutrition. 1, 8–14 (2013). Available from: http://www.unicef.it/Allegati/Improving_Child_Nutrition.pdf.
- Maternal and child undernutrition: global and regional exposures and health consequences.Lancet. 2008; 371: 243-260
- Implications of acquired environmental enteric dysfunction for growth and stunting in infants and children living in low- and middle-income countries.Food Nutr Bull. 2013; 34: 357-364
- Child undernutrition, tropical enteropathy, toilets, and handwashing.Lancet. 2009; 374: 1032-1035
- Environmental enteropathy: critical implications of a poorly understood condition.Trends Mol Med. 2012; 18: 328-336
- Assessment of environmental enteropathy in the MAL-ED cohort study: theoretical and analytic framework.Clin Infect Dis. 2014; 59: S207-S212
- Use of the lactulose to mannitol ratio to evaluate childhood environmental enteric dysfunction: a systematic review.Clin Infect Dis. 2014; 59: S213-S219
- RNA sequencing: platform selection, experimental design, and data interpretation.Nucleic Acid Ther. 2012; 22: 271-274
- Abnormal gut integrity is associated with reduced linear growth in rural Malawian children.J Pediatr Gastroenterol Nutr. 2012; 55: 747-750
- Intestinal permeability, and growth faltering in Gambian infants.Lancet. 1991; 338: 907-910
- Gut microbiomes of Malawian twin pairs discordant for kwashiorkor.Science. 2013; 339: 548-554
- Zinc or albendazole attenuates the progression of environmental enteropathy: a randomized controlled trial.Clin Gastroenterol Hepatol. 2014; 12: 1507-1513
- Multiple micronutrient supplementation transiently ameliorates environmental enteropathy in Malawian children aged 12–35 months in a randomized controlled clinical trial.J Nutr. 2014; 144: 2059-2065
- Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome.J Pediatr. 2008; 153: 646-650
- Double-blind, placebo-controlled trial of rifaximin, a non-absorbable antibiotic, in the treatment of sub-clinical tropical enteropathy.Am J Gastroenterol. 2009; 104: 2326-2333
- P582 Highly efficient extraction of pathogen DNA from stool using the NucliSENS easyMAG TM specific A 1.0.2 protocol.Int J Antimicrobial Agents. 2007; 29: S134
- Evaluation of four different systems for extraction of RNA from stool suspensions using MS-2 coliphage as an exogenous control for RT-PCR inhibition.PLoS One. 2012; 7: e39455
- Comparison of automated nucleic acid extraction methods with manual extraction.J Mol Diagn. 2008; 10: 311-316
- Evaluation of NucliSens easyMAG for automated nucleic acid extraction from various clinical specimens.J Clin Microbiol. 2007; 45: 421-425
- Metagenomic analyses of viruses in stool samples from children with acute flaccid paralysis.J Virol. 2009; 83: 4642-4651
- Detection of low-concentration host mRNA transcripts in Malawian children at risk for environmental enteropathy.J Pediatr Gastroenterol Nutr. 2013; 56: 66-71
- Multiplexed target detection using DNA-binding dye chemistry in droplet digital PCR.Anal Chem. 2013; 85: 11619-11627
- Low-level detection and quantitation of cellular HIV-1 DNA and 2-LTR circles using droplet digital PCR.J Virol Methods. 2012; 186: 68-72
Affymetrix. DataSheet GeneChip® Human Transcriptome Array 2.0. Available from: http://media.affymetrix.com/support/technical/datasheets/hta_array_2_0_datasheet.pdf.
- Exploration, normalization, and summaries of high density oligonucleotide array probe level data.Biostatistics. 2003; 4: 249-264
- Iterative rank-order normalization of gene expression microarray data.BMC Bioinformatics. 2013; 14: 153
- A new summarization method for Affymetrix probe level data.Bioinformatics. 2006; 22: 943-949
- Limma powers differential expression analysis for RNA-sequencing and microarray studies.Nucleic Acids Res. 2015; 43: e47
- Pathway mapping tools for analysis of high content data.Methods Mol Biol. 2007; 356: 319-350
- GAGE: generally applicable gene set enrichment for pathway analysis.BMC Bioinformatics. 2009; 10: 161
Affymetrix. Human transcriptome array 2.0-support materials. Sample data WT PLUS HTA 2.0 data on tissue panel samples (zip, 756 MB). Available from: http://www.affymetrix.com/support/technical/byproduct.affx?product=human_transcriptome.
- Noninvasive stool-based detection of infant gastrointestinal development using gene expression profiles from exfoliated epithelial cells.Am J Physiol Gastrointest Liver Physiol. 2010; 298: 582-589
- Non-invasive analysis of intestinal development in preterm and term infants using RNA-Sequencing.Sci Rep. 2014; 4: 1-9
- Comparability of microarray data between amplified and non-amplified RNA in colorectal carcinoma.J Biomed Biotechnol. 2009; 2009: 837170
- Proinflammatory fecal mRNA and childhood bacterial enteric infections.Gut Microbes. 2010; 1: 209-212
- G-CSF drives a posttraumatic immune program that protects the host from infection.J Immunol. 2014; 192: 2405-2417
- Inhibition of intestinal epithelial apoptosis improves survival in a murine model of radiation combined injury.PLoS One. 2013; 8: e77203
- In vitro and in vivo protective effects of granulocyte colony-stimulating factor against radiation-induced intestinal injury.Arch Pharm Res. 2013; 36: 1252-1261
- Role of granulocyte colony-stimulating factor in paclitaxel-induced intestinal barrier breakdown and bacterial translocation in rats.Chin Med J. 2011; 124: 1870-1875
- Review: enteropathies in the developing world: neglected effects on global health.Am J Trop Med. 2012; 86: 756-763
- Aberrant intestinal expression and allelic variants of mucin genes associated with inflammatory bowel disease.J Mol Med. 2006; 84: 1055-1066
- The mucus and mucins of the goblet cells and enterocytes provide the first defense line of gastrointestinal tract and interact with the immune system.Immunol Rev. 2014; 260: 8-20
- Colitogenic bacteroides thetaiotaomicron antigens access host immune cells in a sulfatase-dependent manner via outer membrane vesicles.Cell Host Microbe. 2015; 17: 672-680
- Geographic variation in the eukaryotic virome of human diarrhea.Virology. 2014; 468–470: 556-564
Article info
Publication history
Footnotes
Conflicts of interest This author discloses the following: Since this work was completed, Erica Barnell started a company, Geneoscopy, which uses RNA detection in feces. The remaining authors disclose no conflicts.
Funding Supported by the Bill & Melinda Gates Foundation and Affymetrix (Santa Clara, CA); by National Institutes of Health grant P30DK052574 (Administrative and Resource Access Care) (P.T.), and Phillip Tarr is a co-inventor on a device to noninvasively measure gut permeability. The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions or policies of the Bill & Melinda Gates Foundation or Affymetrix.
Identification
Copyright
User license
Creative Commons Attribution (CC BY 4.0) |
Permitted
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
Elsevier's open access license policy